Abbvie Inc banner

Abbvie Inc
LSE:0QCV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
LSE:0QCV
Watchlist
Price: 257.5 USD 0.78% Market Closed
Market Cap: $454.7B

Wall St Price Targets

0QCV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast 0QCV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0QCV is 260.78 USD with a low forecast of 198.89 USD and a high forecast of 344.66 USD.

Lowest Forecast
Price Target
198.89 USD
23% Downside
Average Forecast
Price Target
260.78 USD
1% Upside
Highest Forecast
Price Target
344.66 USD
34% Upside
Abbvie Inc Competitors:
Price Targets
ARDX
Ardelyx Inc
225% Upside
CIGI
Colliers International Group Inc
14% Upside
PRQR
ProQR Therapeutics NV
413% Upside

Revenue
Forecast

9% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 5%.

Gross Profit
Forecast

9% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
9% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 7%.

Operating Income
Forecast

12% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
12% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 8 years is 12%.

Pre-Tax Income
Forecast

4% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss
4% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 81%.

Net Income
Forecast

1% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss
1% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 31%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0QCV's stock price target?
Price Target
260.78 USD

According to Wall Street analysts, the average 1-year price target for 0QCV is 260.78 USD with a low forecast of 198.89 USD and a high forecast of 344.66 USD.

What is the Revenue forecast for Abbvie Inc?
Projected CAGR
5%

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 5%.

What is the Gross Profit forecast for Abbvie Inc?
Projected CAGR
7%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 7%.

What is the Operating Income forecast for Abbvie Inc?
Projected CAGR
12%

Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 8 years is 12%.

What is the Pre-Tax Income forecast for Abbvie Inc?
Projected CAGR
81%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 81%.

What is the Net Income forecast for Abbvie Inc?
Projected CAGR
31%

Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 31%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett